logo.png
Cabaletta Bio Announces Pricing of Initial Public Offering
October 25, 2019 07:36 ET | Cabaletta Bio
PHILADELPHIA, Oct. 25, 2019 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical stage biotechnology company focused on the discovery and development of engineered T cell therapies for...
logo.png
Cabaletta Bio Announces Presentation of Preclinical Data Showing Specific CAAR T Activity against Anti-MuSK Expressing B Cells
October 07, 2019 09:00 ET | Cabaletta Bio
Study to be presented by the laboratory of University of Pennsylvania professor Aimee Payne, M.D., Ph.D., Cabaletta co-founder and Scientific Advisory Board co-chair, as a highlighted abstract at the...
logo.png
Cabaletta Bio Receives IND Clearance from FDA to Initiate First Clinical Trial of DSG3-CAART in Patients with Mucosal Pemphigus Vulgaris
October 01, 2019 09:00 ET | Cabaletta Bio
First IND clearance of a product candidate derived from the CABA™ platform PHILADELPHIA, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Company), a clinical-stage biotechnology company...
logo.png
Cabaletta Bio Expands Management Team with Appointment of Brian Stalter as General Counsel
September 05, 2019 10:30 ET | Cabaletta Bio
PHILADELPHIA, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc., a biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune...
logo.png
Autoimmune Clinical Drug Development Expert, David J. Chang, M.D., M.P.H., Joins Cabaletta Bio as Chief Medical Officer
July 15, 2019 08:00 ET | Cabaletta Bio
PHILADELPHIA, July 15, 2019 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc., a biotechnology company focused on the discovery and development of cellular therapies for B cell-mediated autoimmune diseases,...
logo.png
Cabaletta Bio Appoints Distinguished Immunotherapist and Cell Therapy Expert, Catherine Bollard, M.D., to its Board of Directors
April 02, 2019 08:00 ET | Cabaletta Bio
RADNOR, Pa., April 02, 2019 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc., a biotechnology company focused on the discovery and development of cellular therapies for B cell-mediated autoimmune diseases,...
logo.png
Cabaletta Bio to Present at the Cowen and Company 39th Annual Healthcare Conference
March 06, 2019 08:00 ET | Cabaletta Bio
RADNOR, Pa., March 06, 2019 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc., a biotechnology company focused on the discovery and development of cellular therapies for B cell-mediated autoimmune diseases,...
logo.png
Cabaletta Bio Appoints Experienced Financial Executive, Richard Henriques, to its Board of Directors
February 19, 2019 08:00 ET | Cabaletta Bio
RADNOR, Pa., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc., a biotechnology company focused on the discovery and development of cellular therapies for B cell-mediated autoimmune diseases,...
logo.png
Cabaletta Bio Appoints Anup Marda as Chief Financial Officer
January 23, 2019 08:00 ET | Cabaletta Bio
Mr. Marda joins Cabaletta with 17 years of financial leadership experience RADNOR, Pa., Jan. 23, 2019 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc., a biotechnology company focused on the discovery and...
logo.png
Cabaletta Bio to Present at the 37th Annual J.P. Morgan Healthcare Conference
January 03, 2019 08:30 ET | Cabaletta Bio
RADNOR, Pa., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Cabaletta Bio Inc., a biotechnology company focused on the discovery and development of cellular therapies for B cell-mediated autoimmune diseases,...